Italy: A new study published in Pediatric Research has questioned the long-standing practice of fluid restriction in preterm infants undergoing pharmacological treatment for hemodynamically significant patent ductus arteriosus (hsPDA). The research, led by Angela Paladini and colleagues from the Dipartimento Universitario Scienze della Vita e Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS—Università Cattolica del Sacro Cuore, Rome, Italy, found that limiting fluids did not improve PDA closure rates but adversely affected growth and recovery outcomes in preterm babies. The single-center retrospective cohort study compared two groups of preterm neonates who received drug treatment for hsPDA. The earlier cohort (2018–2020) was managed under a fluid-re

See Full Page